Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)

I. Vergote, N. J. Finkler, J. B. Hall, O. Melnyk, R. P. Edwards, M. Jones, L. Meng, G. L. Brown, E.M. Rankin, J. J. Burke, P. G. Rose

    Research output: Contribution to journalMeeting abstract

    Original languageEnglish
    Article number5552
    Pages (from-to)-
    Number of pages2
    JournalJournal of Clinical Oncology
    Volume27
    Issue number15 Suppl.
    Publication statusPublished - 2009
    EventAmerican Society of Clinical Oncology 45th Annual Meeting - Orlando, United States
    Duration: 29 May 20092 Jun 2009
    http://am.asco.org/

    Cite this

    Vergote, I., Finkler, N. J., Hall, J. B., Melnyk, O., Edwards, R. P., Jones, M., Meng, L., Brown, G. L., Rankin, E. M., Burke, J. J., & Rose, P. G. (2009). Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC). Journal of Clinical Oncology, 27(15 Suppl.), -. [5552]. http://jco.ascopubs.org/content/by/year/2009